Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Corporate
  5. Sales Force

Sales Force

Thumbnail
November 19, 2021

Covid-19 takes its toll on medtechs’ efficiency

Staffing levels changed little across 2020 as M&A slowed – but sales are another story.

Thumbnail
September 03, 2020

Medtechs that book the most sales per employee face the greatest losses

Welcome to the calm before the Covid-19 storm.

Article image
Vantage logo
August 22, 2019

The extremes converge in big medtech’s hiring practices

Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.

Article image
Vantage logo
June 21, 2019

Abbvie proves the best at getting the most out of its workers

On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards. 

Article image
Vantage logo
July 23, 2018

Big pharma proves that oncology pays as workforces shrink

Bristol-Myers Squibb has come out on top of an analysis of efficiency in big pharma. Being in immuno-oncology might have helped – but so might aggressive job cuts.

Vantage logo
October 16, 2017

Intuitive finally gets some US competition

Vantage logo
September 21, 2017

Mazor reaches Europe under Medtronic’s auspices

Vantage logo
September 08, 2016

With exec reboot, Novo concedes diabetes is a new game

Vantage logo
August 16, 2016

Slimmed-down big pharma starts growing again

Vantage logo
February 17, 2016

Stryker to enter top five with $1.3bn Physio-Control buy

Vantage logo
August 11, 2015

Mallinckrodt buys cancer cell therapy for $1.3bn

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.